Literature DB >> 29556691

Quantitative dynamic contrast-enhanced MR imaging for differentiating benign, borderline, and malignant ovarian tumors.

Hai-Ming Li1,2, Feng Feng2, Jin-Wei Qiang3, Guo-Fu Zhang4, Shu-Hui Zhao5, Feng-Hua Ma6, Yong-Ai Li1, Wei-Yong Gu7.   

Abstract

PURPOSE: This study aimed to investigate the diagnostic performance of quantitative DCE-MRI for characterizing ovarian tumors.
METHODS: We prospectively assessed the differences of quantitative DCE-MRI parameters (Ktrans, kep, and ve) among 15 benign, 28 borderline, and 66 malignant ovarian tumors; and between type I (n = 28) and type II (n = 29) of epithelial ovarian carcinomas (EOCs). DCE-MRI data were analyzed using whole solid tumor volume region of interest (ROI) method, and quantitative parameters were calculated based on a modified Tofts model. The non-parametric Kruskal-Wallis test, Mann-Whitney U test, Pearson's chi-square test, intraclass correlation coefficient (ICC), variance test, and receiver operating characteristic curves (ROC) were used for statistical analysis.
RESULTS: The largest Ktrans and kep values were observed in ovarian malignant tumors, followed by borderline and benign tumors (all P < 0.001). Kep was the better parameter for differentiating benign tumors from borderline and malignant tumors, with a sensitivity of 89.3% and 95.5%, a specificity of 86.7% and 100%, an accuracy of 88.4% and 96.3%, and an area under the curve (AUC) of 0.94 and 0.992, respectively, whereas Ktrans was better for differentiating borderline from malignant tumors with a sensitivity of 60.7%, a specificity of 78.8%, an accuracy of 73.4%, and an AUC of 0.743. In addition, a combination with kep could further improve the sensitivity to 78.9%. The median Ktrans and kep values were significantly higher in type II than in type I EOCs.
CONCLUSION: DCE-MRI with volume quantification is a technically feasible method, and can be used for the differentiation of ovarian tumors and for discriminating between type I and type II EOCs.

Entities:  

Keywords:  Benign tumor; Borderline tumor; Dynamic contrast-enhanced MR imaging; Malignant tumor; Ovary

Year:  2018        PMID: 29556691     DOI: 10.1007/s00261-018-1569-1

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  10 in total

1.  Magnetic resonance relaxometry improves the accuracy of conventional MRI in the diagnosis of endometriosis-associated ovarian cancer: A case report.

Authors:  Sho Matsubara; Naoki Kawahara; Akihito Horie; Ryusuke Murakami; Naoki Horikawa; Daichi Sumida; Takuya Wada; Tomoka Maehana; Aika Yamawaki; Mayuko Ichikawa; Chiharu Yoshimoto; Masaki Mandai; Hiroshi Kobayashi
Journal:  Mol Clin Oncol       Date:  2019-07-01

2.  Dynamic contrast-enhanced MRI parametric mapping using high spatiotemporal resolution Golden-angle RAdial Sparse Parallel MRI and iterative joint estimation of the arterial input function and pharmacokinetic parameters.

Authors:  Yousef Mazaheri; Nathanael Kim; Yulia Lakhman; Ramin Jafari; Alberto Vargas; Ricardo Otazo
Journal:  NMR Biomed       Date:  2022-03-14       Impact factor: 4.478

3.  Study on the Effect of MRI in the Diagnosis of Benign and Malignant Thoracic Tumors.

Authors:  Yan Li; Yangli Sui; Mingyan Chi; Jie Zhang; Lin Guo
Journal:  Dis Markers       Date:  2021-12-20       Impact factor: 3.434

Review 4.  [Adnexal Masses: Clinical Application of Multiparametric MR Imaging & O-RADS MRI].

Authors:  So Young Eom; Sung Eun Rha
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-09-15

5.  Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer.

Authors:  Rong Hu; Gulina Shahai; Hui Liu; Yuling Feng; Hong Xiang
Journal:  Front Surg       Date:  2022-05-27

Review 6.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

Review 7.  Serous borderline ovarian tumours: an extensive review on MR imaging features.

Authors:  Hilal Sahin; Asli Irmak Akdogan; Janette Smith; Jeries Paolo Zawaideh; Helen Addley
Journal:  Br J Radiol       Date:  2021-07-08       Impact factor: 3.629

8.  MR imaging in discriminating between benign and malignant paediatric ovarian masses: a systematic review.

Authors:  Lotte W E van Nimwegen; Annelies M C Mavinkurve-Groothuis; Ronald R de Krijger; Caroline C C Hulsker; Angelique J Goverde; József Zsiros; Annemieke S Littooij
Journal:  Eur Radiol       Date:  2019-09-16       Impact factor: 5.315

9.  Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumors for T1 and T2 Mapping in a PET/MR Setting.

Authors:  Joshua D Kaggie; Surrin Deen; Dimitri A Kessler; Mary A McLean; Guido Buonincontri; Rolf F Schulte; Helen Addley; Evis Sala; James Brenton; Martin J Graves; Ferdia A Gallagher
Journal:  IEEE Trans Radiat Plasma Med Sci       Date:  2019-03-15

10.  Two-dimensional and three-dimensional T2 weighted imaging-based radiomic signatures for the preoperative discrimination of ovarian borderline tumors and malignant tumors.

Authors:  Xuefen Liu; Tianping Wang; Guofu Zhang; Keqin Hua; Hua Jiang; Shaofeng Duan; Jun Jin; He Zhang
Journal:  J Ovarian Res       Date:  2022-02-03       Impact factor: 4.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.